Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,959 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jové J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-Réglat A; ETNA study group. Rouyer M, et al. Among authors: michel p. Target Oncol. 2016 Feb;11(1):83-92. doi: 10.1007/s11523-015-0377-6. Target Oncol. 2016. PMID: 26298481
Metastatic colorectal cancer.
Bouche O, Conroy T, Michel P, Penna C, Tournigand C. Bouche O, et al. Among authors: michel p. Gastroenterol Clin Biol. 2006 Sep;30 Spec No 2:2S30-2S42. Gastroenterol Clin Biol. 2006. PMID: 17151561 Free article. Review. No abstract available.
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot F, Michel P, Frebourg T. Di Fiore F, et al. Among authors: michel p. Br J Cancer. 2007 Apr 23;96(8):1166-9. doi: 10.1038/sj.bjc.6603685. Epub 2007 Mar 20. Br J Cancer. 2007. PMID: 17375050 Free PMC article.
Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
Hebbar M, Di Fioré F, Conroy T, Giraud C, Gasnault L, Fournier C, Péreira R, Bouché O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A. Hebbar M, et al. Among authors: michel p. Oncology. 2007;73(3-4):185-91. doi: 10.1159/000127385. Epub 2008 Apr 16. Oncology. 2007. PMID: 18418011
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.
Oden-Gangloff A, Di Fiore F, Bibeau F, Lamy A, Bougeard G, Charbonnier F, Blanchard F, Tougeron D, Ychou M, Boissière F, Le Pessot F, Sabourin JC, Tuech JJ, Michel P, Frebourg T. Oden-Gangloff A, et al. Among authors: michel p. Br J Cancer. 2009 Apr 21;100(8):1330-5. doi: 10.1038/sj.bjc.6605008. Br J Cancer. 2009. PMID: 19367287 Free PMC article.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. Conroy T, et al. Among authors: michel p. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923. N Engl J Med. 2011. PMID: 21561347 Free article. Clinical Trial.
[Chemotherapy and rectal cancer].
Michel P, Di Fiore F. Michel P, et al. Cancer Radiother. 2011 Oct;15(6-7):436-9. doi: 10.1016/j.canrad.2011.06.002. Epub 2011 Aug 31. Cancer Radiother. 2011. PMID: 21885319 Review. French.
1,959 results